Selenium-Methionine-Folic Acid Nanoparticles (SeMetFa NPs) and Its In Vivo Efficacy Against Rheumatoid Arthritis.

Abstract

Selenium nanoparticles can be beneficial against rheumatoid arthritis, with limitations in dosage formulation due to their toxicity and low bioavailability. In the present study, we investigated the bioavailability and in vivo efficiency of selenium-methionine-folic acid nanoparticles (SeMetFa NPs) in chronic inflammatory arthritis in rats. The purpose of this study was to develop a therapeutic agent that is of low toxicity and readily available for the maintenance of rheumatoid arthritis. SeMetFa NPs were synthesised by a wet chemical method (precipitation using a reducing agent). The apparent permeability (Papp) of NPs was investigated to be 10 × 10-6cm/s. The effect of selenium-methionine-folic acid nanoparticles (SeMetFa NPs) on rats was investigated for oxidative status, anti-inflammatory markers, physical characteristics, radiography of the paw region, and histopathology. Groups with 250 and 500 mg/kg b.w SeMetFa NPs acted as a potent anti-inflammatory agent with reduced (p < 0.05) arthritis-induced parameters in a 21-day study on Wistar rats. The antioxidant enzyme levels in the liver, kidney, and spleen were restored significantly at 500 and 750 mg/kg b.w. Concluding SeMetFa NPs at a concentration of 500 mg/kg b.w. can be a potential therapeutic agent as compared to dextrin-coated nanoparticles.